Bleomycin – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 74 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page11 sections

Article Summary

Bleomycin is a cytotoxic antibiotic that is used as an anticancer agent in the therapy of testicular and germ cell cancers, Hodgkin disease, lymphomas, and tumors of the head and neck. Therapy with bleomycin in combination with other agents is often associated with mild-to-moderate serum enzyme elevations but is a rare cause of clinically apparent liver injury. Bleomycin A2 is the primary bleomycin species in bleomycin...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindication in simple medical language.
This article explains Dosage in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

72/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Diseases A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Bleomycin is a cytotoxic antibiotic that is used as an anticancer agent in the therapy of testicular and germ cell cancers, Hodgkin disease, lymphomas, and tumors of the head and neck. Therapy with bleomycin in combination with other agents is often associated with mild-to-moderate serum enzyme elevations but is a rare cause of clinically apparent liver injury.

Bleomycin A2 is the primary bleomycin species in bleomycin sulfate, a mixture of the sulfate salts of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin A2 forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)

Bleomycin Sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.

Mechanism of Action

Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. As evident in _in vitro_ studies, the DNA-cleaving actions of bleomycin are dependent on oxygen and metal ions. It is believed that bleomycin chelates metal ions (primarily iron) producing a pseudonym that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.

The cytotoxic action of bleomycin results from its ability to cause fragmentation of DNA. Studies in vitro indicate that bleomycin causes the accumulation of cells in the G2 phase of the cell cycle, and many of these cells display chromosomal aberrations, incl chromatid breaks, gaps, and fragments, as well as translocations. Bleomycin appears to cause the scission of DNA by interacting with oxygen and iron(2+). In the presence of oxygen and a reducing agent, such as dithiothreitol, the metallobleomycin complex becomes activated and functions mechanistically as a ferrous oxidase, transferring electrons from iron(2) to molecular oxygen to produce activated species of oxygen. It has also been shown that metallobleomycin complexes can be activated by a reaction with the flavin enzyme, NADPH-cytochrome p450 reductase. Bleomycin binds to DNA through its amino-terminal peptide, and the activated complex generates free radicals that are responsible for the scission of the DNA chain.

Indications

For palliative treatment in the management of malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Lymphoma, Hodgkins
Non-Hodgkin’s Lymphoma (NHL)
Pleural Effusion, Malignant
Squamous Cell Carcinoma (SCC)
Teratocarcinoma
Testicular Choriocarcinoma
Testicular Embryonal Carcinoma

Use in Cancer

Bleomycin sulfate is approved to be used alone or with other drugs as palliative treatment of:

Hodgkin lymphoma.
Non-Hodgkin lymphoma (NHL).
Squamous cell carcinoma of the penis.
Squamous cell carcinoma of the cervix.
Squamous cell carcinoma of the head and neck (SCCHN).
Squamous cell carcinoma of the vulva.
Testicular cancer.

Bleomycin sulfate is also approved to treat malignant pleural effusion and keep it from recurring (coming back).

Bleomycin sulfate is also being studied in the treatment of other types of cancer.

Contraindication

Hypersensitivity to the active component or any of the ingredients
a type of inflammation of the lung called interstitial pneumonitis
a condition where there is a formation of fibrous tissue in the lung called pulmonary fibrosis
pregnancy
a patient who is producing milk and breastfeeding
chronic obstructive pulmonary disease
chronic kidney disease stage 3A (moderate)
chronic kidney disease stage 3B (moderate)
chronic kidney disease stage 4 (severe)
chronic kidney disease stage 5 (failure)
kidney disease with likely reduction in kidney function

Dosage

Strengths: 15 units; 30 units; 15,000 intl units

Squamous Cell Carcinoma

0.25 to 0.5 units/kg (10 to 20 units/m2) IV, IM, or subcutaneously 1 to 2 times a week
Squamous cell carcinoma sometimes requires 3 weeks before any improvement is noted.
When this drug is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses.

Non-Hodgkin’s Lymphoma

0.25 to 0.5 units/kg (10 to 20 units/m2) IV, IM, or subcutaneously 1 to 2 times a week
Because of the possibility of an anaphylactic reaction, the manufacturer recommends that lymphoma patients be treated with 2 units or less for the first 2 doses. If no acute reaction occurs, then the regular dosage schedule may be followed.

Testicular Cancer

0.25 to 0.5 units/kg (10 to 20 units/m2) IV, IM, or subcutaneously 1 to 2 times a weekHodgkin’s Disease
0.25 to 0.5 units/kg (10 to 20 units/m2) IV, IM, or subcutaneously 1 to 2 times a week; after a 50% response, a maintenance dose of 1 unit daily or 5 units weekly IV or IM should be given

Malignant Pleural Effusion

60 units administered as a single bolus intrapleural injection
When this drug is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses.

Renal Dose Adjustments

The manufacturer recommends the following dose adjustments in patients with renal impairment:

CrCl 50 mL/minute or greater: No adjustment is recommended.
CrCl 40 to 50 mL/minute: Administer 70% of the normal dose.
CrCl 30 to 40 mL/minute: Administer 60% of the normal dose.
CrCl 20 to 30 mL/minute: Administer 55% of the normal dose.
CrCl 10 to 20 mL/minute: Administer 45% of the normal dose.
CrCl 5 to 10 mL/minute: Administer 40% of the normal dose.

Side Effects

The Most Common

redness, blistering, tenderness, or thickening of the skin
darkened skin color
rash
hair loss
sores on the mouth or tongue
vomiting
loss of appetite
weight loss
sudden numbness or weakness of the face, arm, or leg on one side of the body
sudden confusion or trouble speaking or understanding
sudden dizziness. loss of balance or coordination
sudden severe headache
chest pain
decreased urination

More Common

appetite loss or weight loss
changes in fingernails or toenails
increased pigmentation of the skin
nausea and vomiting
skin rash; itching; colored bumps; or peeling of fingertips, elbows, or palms
sudden chest pain, shortness of breath, dry cough, tiredness;
a light-headed feeling, feeling like you might pass out;
loss of appetite, weight loss;
sudden numbness or weakness on one side of the body, problems with vision or speech;
blisters or ulcers in your mouth, red or swollen gums, trouble swallowing;
unusual hardening of your skin; or
swelling, numbness, tingling or cold feeling in your fingers.
skin redness or tenderness
swelling or redness of the hands and feet
temporary loss of hair

Rare

signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
signs of kidney problems (e.g., decreased urination, nausea, vomiting, swelling of the feet and ankles)
signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
signs of lung inflammation (e.g., cough, shortness of breath, noisy breathing, decreased blood pressure)
sores in mouth and on lips
confusion
fever and chills occurring within 4 to 10 hours of dose; may last up to 48 hours
signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat)
sudden and severe chest pain
wheezing

Drug Interaction

DRUG	INTERACTION
Abacavir	Bleomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abatacept	The risk or severity of adverse effects can be increased when Bleomycin is combined with Abatacept.
Aceclofenac	Aceclofenac may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Acetaminophen	Bleomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Bleomycin.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Aclidinium	Bleomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Bleomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Bleomycin.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Adenovirus type 7	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bleomycin.
Albutrepenonacog alfa	Bleomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bleomycin.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Bleomycin.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleomycin.
Allogeneic processed	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bleomycin.
Allopurinol	Bleomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almasilate	Bleomycin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Bleomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	Bleomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alprazolam	Bleomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Altretamine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Altretamine.
Amantadine	Bleomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.
Amikacin	Bleomycin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	Aminophenazone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Amitriptyline	Bleomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
Ammonium chloride	Bleomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amoxicillin	Bleomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ampicillin	Bleomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone	Bleomycin may decrease the excretion rate of Amrinone which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Bleomycin.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Bleomycin.
Anastrozole	The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Anastrozole.
Ancestim	Bleomycin may decrease the excretion rate of Ancestim which could result in a higher serum level.
Anifrolumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Anifrolumab.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bleomycin.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Bleomycin.
Antihemophilic	Bleomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antilymphocyte	The risk or severity of adverse effects can be increased when Bleomycin is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	Antipyrine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Antithrombin III	Bleomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleomycin.
Antrafenine	Antrafenine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Apalutamide	Bleomycin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apremilast	The risk or severity of adverse effects can be increased when Bleomycin is combined with Apremilast.
Arformoterol	Bleomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Arsenic trioxide.
Articaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Articaine.
Ascorbic acid	The therapeutic efficacy of Bleomycin can be decreased when used in combination with Ascorbic acid.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bleomycin.
Atazanavir	Atazanavir may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Atomoxetine	Atomoxetine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Auranofin	Bleomycin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Bleomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Azacitidine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Azathioprine.
Azelaic acid	Bleomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Aztreonam	Bleomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Bacillus antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bleomycin.
Bacillus calmette-	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bleomycin.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bleomycin.
Bacitracin	Bacitracin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Balsalazide	Balsalazide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Baricitinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleomycin.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Bleomycin.
Beclomethasone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Beclomethasone dipropionate.
Belatacept	The risk or severity of adverse effects can be increased when Bleomycin is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Bleomycin is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Bleomycin is combined with Belumosudil.
Bendamustine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bendamustine.
Bendroflumethiazide	Bendroflumethiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Benserazide	Bleomycin may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Benznidazole	Bleomycin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Benzyl alcohol.
Bepotastine	Bleomycin may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Betamethasone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Betamethasone.
Bevacizumab	The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bleomycin.
Bexarotene	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bexarotene.
Bicisate	Bleomycin may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bimekizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bimekizumab.
Bismuth subgallate	Bleomycin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	Bleomycin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Bisoxatin	Bleomycin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Blinatumomab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Blinatumomab.

Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Bleomycin.
Bosutinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of pulmonary toxicity can be increased when Brentuximab vedotin is combined with Bleomycin.
Brivaracetam	Bleomycin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Brodalumab.
Bromazepam	Bleomycin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Budesonide.
Bumadizone	Bumadizone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Bupivacaine.
Bupropion	Bleomycin may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buspirone	Bleomycin may decrease the excretion rate of Buspirone which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Bleomycin is combined with Busulfan.
Butabarbital	Butabarbital may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cabazitaxel.
Calcium ascorbate	The therapeutic efficacy of Bleomycin can be decreased when used in combination with Calcium ascorbate.
Canagliflozin	Canagliflozin may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Canakinumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Canakinumab.
Canrenoic	Canrenoic acid may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Capecitabine.
Capreomycin	Bleomycin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Capsaicin.
Carbamazepine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Carbamazepine.
Carbidopa	Carbidopa may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Carboplatin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Bleomycin.
Carprofen	Carprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefaclor	Cefaclor may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefdinir	Bleomycin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ceftolozane	Bleomycin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cephalexin	Cephalexin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Bleomycin is combined with Certolizumab pegol.
Cetirizine	Bleomycin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Cevimeline	Cevimeline may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Chloral hydrate	Bleomycin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Chlorambucil	The risk or severity of adverse effects can be increased when Bleomycin is combined with Chlorambucil.
Chloramphenicol	The risk or severity of adverse effects can be increased when Bleomycin is combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Chloroprocaine.
Chloroquine	Bleomycin may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Bleomycin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpromazine	Bleomycin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
Chlorpropamide	Bleomycin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Bleomycin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Choline C 11	Bleomycin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium trisalicylate	Choline magnesium trisalicylate may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Choline salicylate	Bleomycin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Bleomycin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Bleomycin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Bleomycin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Bleomycin may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Bleomycin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Bleomycin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Bleomycin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ciclesonide.
Cidofovir	Cidofovir may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cilostazol	Bleomycin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
Cimetidine	Bleomycin may decrease the excretion rate of Cimetidine which could result in a higher serum level.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Cinchocaine.
Ciprofloxacin	Bleomycin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
Cisplatin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Bleomycin.
Clevidipine	Bleomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clobazam	Bleomycin may decrease the excretion rate of Clobazam which could result in a higher serum level.

Clobetasol propionate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Clofarabine.
Clomipramine	Bleomycin may decrease the excretion rate of Clomipramine which could result in a higher serum level.
Clonazepam	Bleomycin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Clorazepic acid	Bleomycin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clostridium tetani	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bleomycin.
Clove oil	Bleomycin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	Bleomycin may decrease the excretion rate of Clozapine which could result in a higher serum level.
Cocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Cocaine.
Colchicine	Bleomycin may decrease the excretion rate of Colchicine which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Colistin	Bleomycin may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated estrogens	Conjugated estrogens may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Corifollitropin alfa	Bleomycin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Corticotropin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bleomycin.
Cyanocobalamin	Cyanocobalamin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cyclophosphamide.
Cyclosporine	Bleomycin may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cytarabine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cytarabine.
Dabigatran etexilate	Bleomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dacarbazine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dacarbazine.
Dactinomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dactinomycin.
Dalfampridine	Bleomycin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin	Daptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bleomycin.
Dasatinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Decitabine.
Deferiprone	Bleomycin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Deflazacort	The risk or severity of adverse effects can be increased when Bleomycin is combined with Deflazacort.
Delafloxacin	Bleomycin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Bleomycin.
Desipramine	Bleomycin may decrease the excretion rate of Desipramine which could result in a higher serum level.
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Bleomycin.
Desmopressin	Desmopressin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Desoximetasone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Desoximetasone.
Desvenlafaxine	Bleomycin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deucravacitinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Deucravacitinib.
Deutetrabenazine	Bleomycin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexamethasone.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Dexmedetomidine	Bleomycin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dexpanthenol	Bleomycin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexrazoxane.
Dextran	Bleomycin may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate	Diatrizoate may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Diazepam	Bleomycin may decrease the excretion rate of Diazepam which could result in a higher serum level.
Dichlorobenzyl alcohol	Bleomycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine	Bleomycin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Bleomycin may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	Bleomycin may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Difluocortolone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Difluocortolone.
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Bleomycin.
Digoxin	Bleomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Dimercaprol	Bleomycin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dimethyl fumarate.
Dimethyl sulfoxide	Bleomycin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Dinutuximab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Diphenhydramine.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Diroximel fumarate.
Disopyramide	Disopyramide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DL-Methylephedrine	Bleomycin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Bleomycin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Docetaxel	The risk or severity of adverse effects can be increased when Bleomycin is combined with Docetaxel.
Dopamine	Bleomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.
Doripenem	Bleomycin may decrease the excretion rate of Doripenem which could result in a higher serum level.
Doxacurium	Bleomycin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Doxepin	Bleomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.
Doxorubicin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Doxorubicin.
Doxycycline	Doxycycline may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Drospirenone	Drospirenone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa	Bleomycin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Duloxetine	Bleomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Dyclonine.
Dyphylline	Bleomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Ebola	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bleomycin.
Eculizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Eculizumab.
Edoxaban	Bleomycin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Bleomycin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleomycin.
Emapalumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Emapalumab.
Enalaprilat	Bleomycin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enzalutamide	Bleomycin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Epirubicin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Epirubicin.
Eplerenone	Eplerenone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	Bleomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Eribulin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Eribulin.
Ertapenem	Bleomycin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.

Estradiol	Bleomycin may decrease the excretion rate of Estradiol which could result in a higher serum level.
Estradiol acetate	Bleomycin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate	Bleomycin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate	Bleomycin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate	Bleomycin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estramustine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Estramustine.
Estrone sulfate	Bleomycin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Eszopiclone	Bleomycin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Bleomycin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Bleomycin.
Ethambutol	Bleomycin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Etomidate	Bleomycin may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel	Bleomycin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Etoposide.
Etoricoxib	Etoricoxib may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Eucalyptus oil	Bleomycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Bleomycin is combined with Everolimus.
Ezogabine	Bleomycin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Fenbufen	Fenbufen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Fenofibrate	Bleomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fenofibric acid	Bleomycin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Bleomycin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Fentanyl	Bleomycin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fesoterodine	Bleomycin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Filgotinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Filgotinib.
Filgrastim	The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin.
Finerenone	Finerenone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Bleomycin may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Bleomycin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Floctafenine	Floctafenine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Florbetaben (18F)	Bleomycin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Bleomycin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Floxuridine.
Fluconazole	Fluconazole may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Flucytosine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fludarabine.
Fludeoxyglucose (18F)	Bleomycin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fludrocortisone.
Flumazenil	Bleomycin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Bleomycin.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocinolone acetonide.
Fluocinonide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluorometholone.
Fluorouracil	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluorouracil.
Fluprednisolone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluprednisolone.
Flurazepam	Bleomycin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Flutamide	Bleomycin may decrease the excretion rate of Flutamide which could result in a higher serum level.
Fluticasone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluticasone propionate.
Fluvoxamine	Fluvoxamine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Folic acid	Folic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Fomepizole	Bleomycin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Bleomycin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Formestane	Bleomycin may decrease the excretion rate of Formestane which could result in a higher serum level.
Foscarnet	Foscarnet may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Fosfomycin	Bleomycin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	Bleomycin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Fosphenytoin	The serum concentration of Fosphenytoin can be decreased when it is combined with Bleomycin.
Framycetin	Framycetin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Gabapentin enacarbil	Bleomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Bleomycin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Gadofosveset trisodium	Bleomycin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Bleomycin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Bleomycin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Bleomycin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Gallium nitrate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Gallium nitrate.
Ganciclovir	Bleomycin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Gemcitabine	The risk or severity of pulmonary toxicity can be increased when Gemcitabine is combined with Bleomycin.
Gemfibrozil	Bleomycin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin.
Gentamicin	Bleomycin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gimeracil	Bleomycin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Glatiramer	The risk or severity of adverse effects can be increased when Bleomycin is combined with Glatiramer.
Glipizide	Bleomycin may decrease the excretion rate of Glipizide which could result in a higher serum level.
Glycerol phenylbutyrate	Bleomycin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Golimumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Golimumab.
Golodirsen	Bleomycin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Guanethidine	Bleomycin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Bleomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Guselkumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Guselkumab.

Iopromide	Bleomycin may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Bleomycin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Bleomycin may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Bleomycin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	Bleomycin may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab	Bleomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Irinotecan	The risk or severity of adverse effects can be increased when Bleomycin is combined with Irinotecan.
Isoniazid	Bleomycin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
Isosorbide	Isosorbide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide mononitrate	Bleomycin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Isosulfan blue	Bleomycin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	Bleomycin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Isoxicam	Isoxicam may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Isradipine	Isradipine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ixabepilone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ixabepilone.
Ixazomib	Bleomycin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ixekizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ixekizumab.
COVID-19 Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Bleomycin.
Japanese encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bleomycin.
Kanamycin	Bleomycin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Bleomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.
Ketazolam	Bleomycin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Ketoprofen	Ketoprofen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Labetalol	Bleomycin may decrease the excretion rate of Labetalol which could result in a higher serum level.
Lamivudine	Bleomycin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamotrigine	Bleomycin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
Latamoxef	Latamoxef may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ledipasvir	Bleomycin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Leflunomide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Lenalidomide.
Lesinurad	Bleomycin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Leuprolide	Leuprolide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Levobupivacaine.
Levocarnitine	Bleomycin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Levocetirizine	Bleomycin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Levofloxacin	Bleomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
Levomilnacipran	Bleomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol	Bleomycin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Lidocaine.
Linezolid	The risk or severity of adverse effects can be increased when Bleomycin is combined with Linezolid.
Liothyronine	Liothyronine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Lisinopril	Bleomycin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Lithium carbonate	Bleomycin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Bleomycin which could result in a higher serum level.

Meperidine	Bleomycin may decrease the excretion rate of Meperidine which could result in a higher serum level.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mercaptopurine.
Meropenem	Bleomycin may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Metamfetamine	Bleomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Metaxalone	Bleomycin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metformin	Bleomycin may decrease the excretion rate of Metformin which could result in a higher serum level.
Methadone	Bleomycin may decrease the excretion rate of Methadone which could result in a higher serum level.
Methazolamide	Methazolamide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The risk or severity of adverse effects can be increased when Bleomycin is combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Methotrexate.
Methoxsalen	Bleomycin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Methoxy polyethylene	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bleomycin.
Methyldopa	Bleomycin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Methylene blue	Bleomycin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Methylnaltrexone	Bleomycin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylprednisolone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Methylprednisolone.
Methyltestosterone	Bleomycin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	Bleomycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Metolazone	Metolazone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Metoprolol may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Metyrapone	Bleomycin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Midazolam	Bleomycin may decrease the excretion rate of Midazolam which could result in a higher serum level.
Migalastat	Bleomycin may decrease the excretion rate of Migalastat which could result in a higher serum level.
Milnacipran	Bleomycin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Milrinone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Mirabegron	Bleomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mitomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mitomycin.
Mitoxantrone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mitoxantrone.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bleomycin.
vaccinia Ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bleomycin.
Mometasone furoate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Monomethyl fumarate.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mosunetuzumab.
Moxisylyte	Bleomycin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Mumps virus strain B	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bleomycin.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Bleomycin.
Muzolimine	Muzolimine may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mycophenolic acid.
N-acetyltyrosine	Bleomycin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Nadolol	Bleomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.
Naldemedine	Bleomycin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene	Bleomycin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxone	Bleomycin may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naproxen	Naproxen may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Natalizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.
Nateglinide	Bleomycin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
Nedaplatin	Bleomycin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Bleomycin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nefazodone	Bleomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Nelarabine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Nelarabine.
Neomycin	Bleomycin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Bleomycin may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Niacinamide	The therapeutic efficacy of Bleomycin can be decreased when used in combination with Niacinamide ascorbate.
Nicorandil	Bleomycin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	Bleomycin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
Nilotinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Nilotinib.
Nilutamide	Bleomycin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nimesulide	Nimesulide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Nisoldipine	Bleomycin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Nitric Oxide	Bleomycin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Nitrofurantoin	Bleomycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.

Obinutuzumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Bleomycin.
Octinoxate	Bleomycin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Ofatumumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ofatumumab.
Olaparib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Olaparib.
Olsalazine	Olsalazine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Opium	Bleomycin may decrease the excretion rate of Opium which could result in a higher serum level.
Oseltamivir	Oseltamivir may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Ouabain	Ouabain may decrease the cardiotoxic activities of Bleomycin.
Oxacillin	Bleomycin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaliplatin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Oxaliplatin.
Oxaprozin	Oxaprozin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Oxazepam	Bleomycin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Oxetacaine.
Oxybenzone	Bleomycin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Oxybuprocaine.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Oxyquinoline	Bleomycin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Ozanimod	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Bleomycin is combined with Paclitaxel.
Palbociclib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Palbociclib.
Paliperidone	Bleomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Palonosetron	Bleomycin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Panobinostat	The risk or severity of adverse effects can be increased when Bleomycin is combined with Panobinostat.
Pantoprazole	Pantoprazole may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Parecoxib	Parecoxib may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Paromomycin	Paromomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Patent Blue	Bleomycin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pazopanib.
Pegaptanib	Bleomycin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleomycin.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bleomycin.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleomycin.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bleomycin.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Bleomycin is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pemetrexed.
Penbutolol	Bleomycin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Penicillamine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Penicillamine.
Pentaerythritol tetranitrate	Bleomycin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Pentastarch	Bleomycin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Bleomycin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Bleomycin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Pentostatin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pentostatin.
Pentoxifylline	Bleomycin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Perindopril	Bleomycin may decrease the excretion rate of Perindopril which could result in a higher serum level.
Permethrin	Bleomycin may decrease the excretion rate of Permethrin which could result in a higher serum level.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bleomycin.
Pertuzumab	The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Pertuzumab.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Phenelzine	Bleomycin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Phenol	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Phenol.
Phentolamine	Bleomycin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleomycin.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Bleomycin.
Pholcodine	Bleomycin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Bleomycin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Bleomycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Picosulfuric acid	Bleomycin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bleomycin.
Pindolol	Bleomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.
Piperacillin	Bleomycin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Piracetam	Bleomycin may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pirfenidone.
Piroxicam	Piroxicam may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Pitolisant	Bleomycin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Plazomicin	Bleomycin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Bleomycin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ponesimod.
Potassium	Potassium may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Bleomycin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate	Bleomycin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium chloride	Bleomycin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate	Bleomycin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium perchlorate	Bleomycin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	Bleomycin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralatrexate	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pralatrexate.
Pralidoxime	Bleomycin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pramipexole	Bleomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Pramocaine.
Prasugrel	Bleomycin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Prednisolone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Prednisone.
Pregabalin	Pregabalin may decrease the excretion rate of Bleomycin which could result in a higher serum level.

Procarbazine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Procarbazine.
Promethazine	Bleomycin may decrease the excretion rate of Promethazine which could result in a higher serum level.
Propantheline	Bleomycin may decrease the excretion rate of Propantheline which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Proparacaine.
Propiverine	Bleomycin may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Propoxycaine.
Propranolol	Bleomycin may decrease the excretion rate of Propranolol which could result in a higher serum level.
Propylthiouracil	The risk or severity of adverse effects can be increased when Bleomycin is combined with Propylthiouracil.
Prucalopride	Bleomycin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pyrantel	Bleomycin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Bleomycin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Pyrithione	Bleomycin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Quetiapine	Bleomycin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Quinethazone	Quinethazone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	Bleomycin may decrease the excretion rate of Quinidine which could result in a higher serum level.
Rabeprazole	Bleomycin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Rabies immune	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bleomycin.
Rabies virus	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bleomycin.
Rabies virus	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bleomycin.
Raltitrexed	The risk or severity of adverse effects can be increased when Bleomycin is combined with Raltitrexed.
Ramelteon	Bleomycin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Ranitidine	Bleomycin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
Ranolazine	Ranolazine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Rasagiline	Bleomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Ravulizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ravulizumab.
Reserpine	Reserpine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Resorcinol	Bleomycin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Ribavirin	Bleomycin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribostamycin	Bleomycin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilonacept	The risk or severity of adverse effects can be increased when Bleomycin is combined with Rilonacept.
Risankizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Risankizumab.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Bleomycin.
Rivaroxaban	Bleomycin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan	Bleomycin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rofecoxib	Rofecoxib may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Bleomycin.
Ropeginterferon	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Ropivacaine.
Rosiglitazone	Bleomycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bleomycin.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bleomycin.
Ruxolitinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Ruxolitinib.
Sacubitril	Bleomycin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	Bleomycin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Sargramostim	The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin.
Sarilumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Satralizumab.
Saxagliptin	Bleomycin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Secobarbital	Bleomycin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Secukinumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Secukinumab.
Selenious acid	Bleomycin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Bleomycin may decrease the excretion rate of Selenium which could result in a higher serum level.
Sibutramine	Bleomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Siltuximab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Siltuximab.
Siponimod	The risk or severity of adverse effects can be increased when Bleomycin is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bleomycin.
Sirolimus	The risk or severity of adverse effects can be increased when Bleomycin is combined with Sirolimus.
Sitagliptin	Bleomycin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Smallpox (Vaccinia)	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bleomycin.
Sodium acetate	Bleomycin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium ascorbate	The therapeutic efficacy of Bleomycin can be decreased when used in combination with Sodium ascorbate.
Sodium aurothiomalate	Bleomycin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium fluoride	Bleomycin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Bleomycin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	Bleomycin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solriamfetol	Bleomycin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Sorafenib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Sorafenib.
Sorbitol	Bleomycin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Spesolimab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Spesolimab.
Spironolactone	Spironolactone may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol	Bleomycin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Streptomycin	Bleomycin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Streptozocin.
Strontium chloride	Bleomycin may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Bleomycin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Sulbactam	Bleomycin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	Bleomycin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bleomycin.
Sulfasalazine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Sulfasalazine.
Sulindac	Sulindac may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Sumatriptan	Bleomycin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Sunitinib.
Estrogens, A	Bleomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Conjugated Estrogens, B	Bleomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Bleomycin.
Tadalafil	Bleomycin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Tamoxifen	The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Tamoxifen.
Tamsulosin	Bleomycin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Tasimelteon	Bleomycin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.

Telavancin	Bleomycin may decrease the excretion rate of Telavancin which could result in a higher serum level.
Temazepam	Temazepam may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Temozolomide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Temozolomide.
Temsirolimus	The risk or severity of adverse effects can be increased when Bleomycin is combined with Temsirolimus.
Teniposide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Teniposide.
Tenofovir alafenamide	Tenofovir alafenamide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Tenofovir disoproxil	Tenofovir disoproxil may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Tenoxicam	Tenoxicam may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Teprotumumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Teprotumumab.
Terbutaline	Bleomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Teriflunomide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Teriflunomide.
Testolactone	Bleomycin may decrease the excretion rate of Testolactone which could result in a higher serum level.
Testosterone	Bleomycin may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone cypionate	Bleomycin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate	Bleomycin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone propionate	Bleomycin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Testosterone undecanoate	Bleomycin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Tetracaine.
Tetracycline	Bleomycin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Tetradecyl hydrogen	Bleomycin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thalidomide	The risk or severity of adverse effects can be increased when Bleomycin is combined with Thalidomide.
Thiabendazole	Bleomycin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Thiethylperazine	Bleomycin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Thiotepa	The risk or severity of adverse effects can be increased when Bleomycin is combined with Thiotepa.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
encephalitis vaccine	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Bleomycin.
Ticlopidine	Ticlopidine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Tiludronic acid	Bleomycin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Timolol	Bleomycin may decrease the excretion rate of Timolol which could result in a higher serum level.
Tinidazole	Bleomycin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tioguanine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Tioguanine.
Tiopronin	Bleomycin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Bleomycin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tirofiban	Bleomycin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Tixocortol	The risk or severity of adverse effects can be increased when Bleomycin is combined with Tixocortol.
Tobramycin	Bleomycin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Tocilizumab.
Tocopherol	Bleomycin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tofacitinib	Bleomycin may increase the immunosuppressive activities of Tofacitinib.
Tolazamide	Bleomycin may decrease the excretion rate of Tolazamide which could result in a higher serum level.
Tolbutamide	Bleomycin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolcapone	Bleomycin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Tolterodine	Bleomycin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Topiramate may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Topotecan	The risk or severity of adverse effects can be increased when Bleomycin is combined with Topotecan.
Torasemide	Torasemide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleomycin.
Trabectedin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Trabectedin.
Tramadol	Tramadol may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Trametinib	Bleomycin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Bleomycin.
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Trastuzumab emtansine.
Tretinoin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Tretinoin.
Triamcinolone	The risk or severity of adverse effects can be increased when Bleomycin is combined with Triamcinolone.
Triamterene	Triamterene may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Bleomycin may decrease the excretion rate of Triazolam which could result in a higher serum level.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
Triethylenetetramine	Bleomycin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluridine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Trifluridine.
Trilostane	The risk or severity of adverse effects can be increased when Bleomycin is combined with Trilostane.
Trimebutine	Bleomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Trimethoprim	Bleomycin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Trimetrexate	Bleomycin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Tropisetron	Bleomycin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bleomycin.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bleomycin.
polysaccharide vaccine	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bleomycin.
Upadacitinib	The risk or severity of adverse effects can be increased when Bleomycin is combined with Upadacitinib.
Vaborbactam	Bleomycin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Valbenazine	Bleomycin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Valganciclovir	Bleomycin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valproic acid	The serum concentration of Valproic acid can be decreased when it is combined with Bleomycin.
Vancomycin	Bleomycin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Varenicline	Bleomycin may decrease the excretion rate of Varenicline which could result in a higher serum level.
Varicella zoster	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Bleomycin.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Bleomycin.
Vedolizumab	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vedolizumab.
Venlafaxine	Venlafaxine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Verapamil	Bleomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Bleomycin.
Vilanterol	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vilanterol.
Viloxazine	Bleomycin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Vinblastine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vinblastine.
Vincristine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vincristine.
Vindesine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vindesine.
Vinorelbine	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vinorelbine.
Voclosporin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Voclosporin.
Vorinostat	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vorinostat.
Vortioxetine	Bleomycin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Warfarin	Bleomycin may decrease the excretion rate of Warfarin which could result in a higher serum level.

Pregnancy and Lactation

FDA Pregnancy Category D

Pregnancy

Studies of this medication have not been done with pregnant women. There is a possibility of birth defects if either the father or mother is using bleomycin at the time of conception, or if it is taken during pregnancy. Effective birth control should be practiced while using this medication. Tell the doctor immediately if you become pregnant while using this medication.

Lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence. Although no data are available to determine an appropriate period to withhold breastfeeding, the drug’s terminal half-life of 4 hours with normal kidney function suggests that withholding breastfeeding for at least 24 hours may be sufficient. This period may be longer in patients with impaired kidney function. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breast milk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.

How should this medicine be used?

Bleomycin comes as a powder to be mixed with liquid and injected intravenously (into a vein), intramuscularly (into a muscle), or subcutaneously (under the skin) by a doctor or nurse in a medical office or hospital outpatient department. It is usually injected once or twice a week. When bleomycin is used to treat pleural effusions, it is mixed with liquid and placed in the chest cavity through a chest tube (plastic tube that is placed in the chest cavity through a cut in the skin).

What special precautions should I follow?

Before taking bleomycin,

tell your doctor and pharmacist if you are allergic to bleomycin or any of the ingredients in bleomycin injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements, you are taking or plan to take. Your doctor may need to monitor you carefully for side effects.
tell your doctor if you have or have ever had kidney or lung disease.
tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant while you are receiving bleomycin injections. If you become pregnant while receiving bleomycin, call your doctor. Bleomycin may harm the fetus.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving bleomycin.

References

https://pubchem.ncbi.nlm.nih.gov/compound/Bleomycin
https://www.ncbi.nlm.nih.gov/books/NBK555895/
https://medlineplus.gov/druginfo/meds/a682125.html
https://www.webmd.com/drugs/2/drug-5069/bleomycin-injection/details/list-contraindications
https://go.drugbank.com/drugs/DB00290
https://www.drugs.com/mtm/bleomycin.html
https://www.medbroadcast.com/drug/getdrug/bleomycin-for-injection-by-pfizer
ChemIDplus

LICENSE

https://www.nlm.nih.gov/copyright.html

Bleomycin [INN:BAN]

https://chem.nlm.nih.gov/chemidplus/sid/0011056067

ChemIDplus Chemical Information Classification

https://chem.nlm.nih.gov/chemidplus/
DrugBank

https://www.drugbank.ca/legal/terms_of_use

Bleomycin

https://www.drugbank.ca/drugs/DB00290
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Bleomycin

https://comptox.epa.gov/dashboard/DTXSID1030862

Bleomycin sulfate

https://comptox.epa.gov/dashboard/DTXSID2047800

Bleomycin A2

https://comptox.epa.gov/dashboard/DTXSID20872327
Hazardous Substances Data Bank (HSDB)

BLEOMYCIN

https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3208
Human Metabolome Database (HMDB)

http://www.hmdb.ca/citing

Bleomycin

http://www.hmdb.ca/metabolites/HMDB0014435
LiverTox

LICENSE

https://www.nlm.nih.gov/copyright.html

Bleomycin

https://www.ncbi.nlm.nih.gov/books/n/livertox/Bleomycin/
LOTUS – the natural products occurrence database

LICENSE

The code for LOTUS is released under the GNU General Public License v3.0.

https://lotus.nprod.net/

LOTUS Tree

https://lotus.naturalproducts.net/
NCI Thesaurus (NCIt)

https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C311

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C313

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C312

NCI Thesaurus Tree

https://ncit.nci.nih.gov
ChEMBL

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3085504/
Comparative Toxicogenomics Database (CTD)

http://ctdbase.org/about/legal.jsp

https://ctdbase.org/detail.go?type=chem&acc=D001761
Therapeutic Target Database (TTD)

Bleomycin

http://idrblab.net/ttd/data/drug/details/D06UVD
ClinicalTrials.gov

https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
DailyMed

LICENSE

https://www.nlm.nih.gov/copyright.html

BLEOMYCIN SULFATE

https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BLEOMYCIN+SULFATE
Drug Induced Liver Injury Rank (DILIrank) Dataset

https://www.fda.gov/about-fda/about-website/website-policies#linking

bleomycin

https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
The Natural Products Atlas

LICENSE

The Natural Products Atlas is licensed under a Creative Commons Attribution 4.0 International License.

https://www.npatlas.org/terms

Bleomycin A2

https://www.npatlas.org/explore/compounds/NPA020036
Drugs and Lactation Database (LactMed)

LICENSE

https://www.nlm.nih.gov/copyright.html

Bleomycin

https://www.ncbi.nlm.nih.gov/books/NBK500695/
EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/
FDA Orange Book

https://www.fda.gov/about-fda/about-website/website-policies#linking

https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
International Agency for Research on Cancer (IARC)

https://publications.iarc.fr/Terms-Of-Use

Bleomycins

https://monographs.iarc.who.int/list-of-classifications

IARC Classification

https://www.iarc.fr/
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

BLEOMYCIN

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

Bleomycin Sulfate

https://www.cancer.gov/about-cancer/treatment/drugs/bleomycin
NIPH Clinical Trials Search of Japan

https://rctportal.niph.go.jp/en/
PubChem

https://pubchem.ncbi.nlm.nih.gov
WHO Anatomical Therapeutic Chemical (ATC) Classification

https://www.whocc.no/copyright_disclaimer/

https://www.whocc.no/atc/

ATC Code

https://www.whocc.no/atc_ddd_index/
WHO Model Lists of Essential Medicines

https://www.who.int/about/who-we-are/publishing-policies/copyright

Bleomycin

https://list.essentialmeds.org/medicines/74
Wikidata

LICENSE

CCZero

https://creativecommons.org/publicdomain/zero/1.0/

Q105203558

https://www.wikidata.org/wiki/Q105203558
Medical Subject Headings (MeSH)

https://www.nlm.nih.gov/copyright.html

Bleomycin

https://www.ncbi.nlm.nih.gov/mesh/68001761

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html

Antibiotics, Antineoplastic

https://www.ncbi.nlm.nih.gov/mesh/68000903
EPA Substance Registry Services

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

EPA SRS List Classification

https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
NCBI

https://www.ncbi.nlm.nih.gov/projects/linkout

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Internal learning pathway

Explore related RX articles

Related guides from RX Harun are grouped to help readers move from overview to symptoms, tests, treatment, and safe next steps.

Drugs (A - Z)

Vasodilator Drugs Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium…
Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine…
Methamphetamine – Uses, Dosage, Side Effects, Interactions Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.…
Vitamin D3 – Uses, Dosage, Side Effects, Interactions DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from…
Imidazole – Uses, Dosage, Side Effects, Interactions DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of…
Carbimazole Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is…

Read, save, and share this guide

Article Summary

Key Takeaways

RX Patient Tools

Mechanism of Action

How should this medicine be used?